Ao Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ao Wang has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Xu Yao
Department of Allergy and Rheumatology, Jiangsu Provincial Key Laboratory of Dermatology, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
4 shared publications - Wei Li
Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China
3 shared publications - Xiaochun Liu
Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China
3 shared publications - Yang Luo
Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China
3 shared publications - Yuan Zhou
Department of Allergy and Rheumatology, Jiangsu Provincial Key Laboratory of Dermatology, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
3 shared publications - Beilei Xu
Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Hospital for Skin Diseases, Institute of Dermatology Chinese Academy of Medical Sciences and Peking Union Medical College Nanjing Jiangsu China
2 shared publications
Latest Publications
- Open Access
- 19 December 2023
- Published by Elsevier in Cell Reports Medicine
- Vol. 4 (12) , 101340
Attenuation of allergen-specific immunotherapy for atopic dermatitis by ectopic colonization of Brevundimonas vesicularis in the intestine
- 19 December 2023
- Published by Elsevier in Cell Reports Medicine
- Vol. 4 (12) , 101340
Open AccessAttenuation of allergen-specific immunotherapy for atopic dermatitis by ectopic colonization of Brevundimonas vesicularis in the intestine
- 2 June 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (12) , 2484-2493.e11
Heterogeneous Regulation of Staphylococcus Aureus by Different Staphylococcus Epidermidis agr Types in Atopic Dermatitis
- 2 June 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (12) , 2484-2493.e11
Heterogeneous Regulation of Staphylococcus Aureus by Different Staphylococcus Epidermidis agr Types in Atopic Dermatitis
- Open Access
- 15 November 2022
- Published by Elsevier in World Allergy Organization Journal
- Vol. 15 (12) , 100719
Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China
- 15 November 2022
- Published by Elsevier in World Allergy Organization Journal
- Vol. 15 (12) , 100719
Open AccessEfficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China
- 8 May 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (11) , 2968-2977.e10
Transglutaminase 3 Attenuates Skin Inflammation in Psoriasis by Inhibiting NF-κB Activation through Phosphorylated STAT3–TET3 Signaling
- 8 May 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (11) , 2968-2977.e10
Transglutaminase 3 Attenuates Skin Inflammation in Psoriasis by Inhibiting NF-κB Activation through Phosphorylated STAT3–TET3 Signaling
- Open Access
- 1 January 2021
- Published by INSTICC
- p. 313-317
Oral Administration of Bovine Blood Peptide Generated No Adverse Effect on Healthy Rats
- 1 January 2021
- Published by INSTICC
- p. 313-317
Open AccessOral Administration of Bovine Blood Peptide Generated No Adverse Effect on Healthy Rats
- Top Cited Papers
- 13 December 2019
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (2) , 104-113
Dendritic cells: The driver of psoriasis
Psoriasis is a chronic skin inflammatory disorder, the immune mechanism of which has been profoundly elucidated in the past few years. The dominance of the interleukin (IL)‐23/IL‐17 axis is a significant breakthrough in the understanding of the pathogenesis of psoriasis, and treatment targeting IL‐23 and IL‐17 has successfully benefited patients with the disease. The skin contains a complex network of dendritic cells (DC) mainly composed of epidermal Langerhans cells, bone marrow‐derived dermal conventional DC, plasmacytoid DC and inflammatory DC. As the prominent cellular source of α‐interferon, tumor necrosis factor‐α, IL‐12 and IL‐23, DC play a pivotal role in psoriasis. Thus, targeting pathogenic DC subsets is a valid strategy for alleviating and preventing psoriasis and other DC‐derived diseases. In this review, we survey the known role of DC in this disease.
- 13 December 2019
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (2) , 104-113
Top Cited PapersDendritic cells: The driver of psoriasis
Psoriasis is a chronic skin inflammatory disorder, the immune mechanism of which has been profoundly elucidated in the past few years. The dominance of the interleukin (IL)‐23/IL‐17 axis is a significant breakthrough in the understanding of the pathogenesis of psoriasis, and treatment targeting IL‐23 and IL‐17 has successfully benefited patients with the disease. The skin contains a complex network of dendritic cells (DC) mainly composed of epidermal Langerhans cells, bone marrow‐derived dermal conventional DC, plasmacytoid DC and inflammatory DC. As the prominent cellular source of α‐interferon, tumor necrosis factor‐α, IL‐12 and IL‐23, DC play a pivotal role in psoriasis. Thus, targeting pathogenic DC subsets is a valid strategy for alleviating and preventing psoriasis and other DC‐derived diseases. In this review, we survey the known role of DC in this disease.